 I'm Deborah Borchart and this is your marijuana money minute. Earning season is underway and with the sector in a bear market there seems to be a lot of pressure on companies to deliver solid results. GW Pharmaceuticals managed to do just that but the stocks still tumble confusing shareholders. The company reported third quarter net sales of $86 million in the cannabis drug Epidiolex. Revenue for the quarter was $91 million and that beat estimates. The losses were cut to $13 million versus last year's net loss of $79 million. Still, the stock sold off. Innovative industrial properties beat analysts' estimates with revenue that rose over 200% to $11 million and earnings per share of $0.55. The dividend increased 30% to $0.78 per share and they're one of the few cannabis companies that even pays a dividend. The stock did jump over 9% on that news. CVScience is though disappointed with revenue of $12.6 million that missed estimates by $6 million. That decline was attributed to reduced sales. No kidding, right? Merit-a-Price did site you to form a $120 million special purchase acquisition company. The symbol will be MCMGU. Tilt holdings closed on a $35 million private placement which will be used to pay off a high interest rate bridge loan. The company also agreed to board changes. Terratech is merging with the over-the-counter drug company, One Core, and they may spin off their cannabis holdings. Suniva lost in CFO, but they said their Canna Farm Rex deal is still on. Metafarm Labs filed to list on the NASDAQ this week, those guys behind me. And that's it. I'm Deborah Bortar reporting for the Green Market Report from Times Square.